Dinitrochlorobenzene immunotherapy of recurrent squamous papilloma of the conjunctiva.
Dinitrochlorobenzene (DNCB) immunotherapy of a recurrent conjunctival papilloma was employed successfully in a 24-year-old man. Previous attempts at electrocautery, surgical excision, and cryosurgery met without success. The tumor response to DNCB therapy resulted in total eradication of the tumor and represents a more successful modality than previous treatments. Poor patient compliance, variable patient immune mechanisms, and tumor size may influence the variable patient immune mechanisms, and tumor size may influence the fate and type of response to DNCb immunotherapy. DNCB therapy should be considered in the treatment of conjunctival papillomas refractory to conventional modes of therapy.
D000328:Adult; D003230:Conjunctival Neoplasms / Q000601:surgery / Q000628:therapy*; D004137:Dinitrochlorobenzene / Q000276:immunology / Q000627:therapeutic use*; D006801:Humans; D006968:Hypersensitivity, Delayed; D007114:Immunization; D007167:Immunotherapy; D008297:Male; D009364:Neoplasm Recurrence, Local; D009578:Nitrobenzenes / Q000627:therapeutic use*; D010212:Papilloma / Q000601:surgery / Q000628:therapy*
D004137:Dinitrochlorobenzene; D009578:Nitrobenzenes